Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

ADGRL2 (adhesion G protein-coupled receptor L2 )

Written2003-11Jim Heighway
Roy Castle International Centre for Lung Cancer Research, Liverpool, UK

(Note : for Links provided by Atlas : click)


Alias (NCBI)LPHN2 (latrophilin 2)
HGNC Alias symbKIAA0786
HGNC Previous nameLPHH1
HGNC Previous namelatrophilin 1
 latrophilin 2
LocusID (NCBI) 23266
Atlas_Id 313
Location 1p31.1  [Link to chromosome band 1p31]
Location_base_pair Starts at 81800397 and ends at 81993932 bp from pter ( according to GRCh38/hg38-Dec_2013)  [Mapping ADGRL2.png]
Local_order --ELTD1---LPHH1----FLJ23033----PRKACB--
  Probe(s) - Courtesy Mariano Rocchi, Resources for Molecular Cytogenetics
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)
ADGRL2 (1p31.1) / ADGRL2 (1p31.1)ADGRL2 (1p31.1) / AK5 (1p31.1)ADGRL2 (1p31.1) / FLNA (Xq28)
ADGRL2 (1p31.1) / MIR548N (2q31.2)BCL6 (3q27.3) / ADGRL2 (1p31.1)STAT6 (12q13.3) / ADGRL2 (1p31.1)


  Representation of the genomic structure of LPHH1. Black blocks represent core exons which are present in the majority of gene transcripts. The yellow blocks represent alternatively spliced coding exons which may be incorporated variably in transcripts derived from different cell types/tissues or as a consequence of differing cellular states. The red boxes represent the presence of multiple, in some cases tissue-specific, leader exons that have been identified for this gene, an observation consistent with the existence of multiple dispersed promoter elements. The most variably spliced region of the coding sequence was the carboxy-terminal domain D.
Description LPHH1 consists of 19 commonly used coding exons. A further seven exons have been identified which may be alternatively spliced into the core backbone with variable frequencies and tissue specificities. At least a number of these additional exons are highly conserved in mammalian species. The core exons (ATG, exon 1 to stop, exon 19) span a region of about 154kb. However, the 5'end of the gene is not precisely defined with transcripts in different tissues apparently initiating from specific locations over an extensive region. The most distant leader exon identified (foetal lung) lies approximately 390kb from exon 1 which makes the total size of the gene at least 550kb.
Transcription Expression has been observed by RT-PCR in all normal tissues and lines tested with the clear exception of lymphocytes and lymphoblastoid cells. Strongest expression was observed in foetal lung, normal adult lung and thyroid. Alternative splicing to some degree in at least one domain (minimally the carboxy-terminal domain D) was seen in each tissue and line examined with human brain showing a characteristic pattern and additional variability in the other three coding sequence domains.
Pseudogene No known pseudogene.


  Alternative splicing in domain D dramatically alters the structure of the carboxy-terminus of the encoded protein, latrophilin 2. Variable splicing in this region occurs in all tissues and cell lines tested.
Description LPHH1 encodes a putative seven-span transmembrane receptor with atypically large extra membrane N (predicted to be extra-cellular) and C termini. In addition to the seven hydrophobic membrane spanning domains, a putative lectin-like region is present near the N-terminus.
Expression Protein likely to be ubiquitously expressed in adherent cells but that has not so far been confirmed. Human brain-specific alternative splices alter the structure of the extra-membrane, intra-cellular loop between TM domains 5 and 6, a region thought to be critical for G-protein/receptor interactions.
Localisation Likely to be plasma membrane.
Function Likely role in coupling cell adhesion to cell signalling.
Homology Latrophilin 2 is part of a small sub-family of 7TMs which includes latrophilins 1 and 3. Latrophilin 1 is the receptor for Black Widow spider toxin: -latrotoxin.


Note None reported.

Implicated in

Entity Breast carcinoma
Note Analysis of breast cancer cell lines has demonstrated dramatic differences in transcript levels between certain lines. In one case, strong expression was allelically imbalanced.
Entity Lung carcinoma
Note strong expression in normal lung was reduced in 55% (35/64) of matched primary non-small cell lung carcinomas (NSCLC). Over-representation was not scored in any tumour, nor in any lung cancer cell line tested and transcript was undetectable by RT-PCR in one line (1/15) and very low in a further two. Loss of heterozygosity was scored in 8/16 informative NSCLC lesions. Primary and SCLC lines showed a characteristic pattern of alternative splicing.


A family of heptahelical receptors with adhesion-like domains: a marriage between two super families.
Hayflick JS
Journal of receptor and signal transduction research. 2000 ; 20 (2-3) : 119-131.
PMID 10994649
Genomic structure and expression profile of LPHH1, a 7TM gene variably expressed in breast cancer cell lines.
White GR, Varley JM, Heighway J
Biochimica et biophysica acta. 2000 ; 1491 (1-3) : 75-92.
PMID 10760572


This paper should be referenced as such :
Heighway, J
LPHN2 (latrophilin 2)
Atlas Genet Cytogenet Oncol Haematol. 2004;8(1):10-11.
Free journal version : [ pdf ]   [ DOI ]

External links

HGNC (Hugo)ADGRL2   18582
Entrez_Gene (NCBI)ADGRL2    adhesion G protein-coupled receptor L2
AliasesCIRL2; CL2; LEC1; LPHH1; 
GeneCards (Weizmann)ADGRL2
Ensembl hg19 (Hinxton)ENSG00000117114 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000117114 [Gene_View]  ENSG00000117114 [Sequence]  chr1:81800397-81993932 [Contig_View]  ADGRL2 [Vega]
ICGC DataPortalENSG00000117114
Genatlas (Paris)ADGRL2
SOURCE (Princeton)ADGRL2
Genetics Home Reference (NIH)ADGRL2
Genomic and cartography
GoldenPath hg38 (UCSC)ADGRL2  -     chr1:81800397-81993932 +  1p31.1   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)ADGRL2  -     1p31.1   [Description]    (hg19-Feb_2009)
GoldenPathADGRL2 - 1p31.1 [CytoView hg19]  ADGRL2 - 1p31.1 [CytoView hg38]
genome Data Viewer NCBIADGRL2 [Mapview hg19]  
Gene and transcription
Genbank (Entrez)AB018329 AF104266 AF104938 AF104939 AJ131581
RefSeq transcript (Entrez)NM_001297704 NM_001297705 NM_001297706 NM_001330645 NM_001350698 NM_001350699 NM_001366002 NM_001366003 NM_001366004 NM_001366005 NM_001366006 NM_001366007 NM_001366008 NM_001366009 NM_001393349 NM_001393350 NM_001393351 NM_001393352 NM_001393353 NM_001393354 NM_012302
RefSeq genomic (Entrez)
Consensus coding sequences : CCDS (NCBI)ADGRL2
Alternative Splicing GalleryENSG00000117114
Gene ExpressionADGRL2 [ NCBI-GEO ]   ADGRL2 [ EBI - ARRAY_EXPRESS ]   ADGRL2 [ SEEK ]   ADGRL2 [ MEM ]
Gene Expression Viewer (FireBrowse)ADGRL2 [ Firebrowse - Broad ]
GenevisibleExpression of ADGRL2 in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)23266
GTEX Portal (Tissue expression)ADGRL2
Human Protein AtlasENSG00000117114-ADGRL2 [pathology]   [cell]   [tissue]
Protein : pattern, domain, 3D structure
Domain families : Pfam (Sanger)
Domain families : Pfam (NCBI)
Conserved Domain (NCBI)ADGRL2
Blocks (Seattle)ADGRL2
Human Protein Atlas [tissue]ENSG00000117114-ADGRL2 [tissue]
IPIIPI00410232   IPI00017562   IPI00410234   IPI00164345   IPI00902461   IPI00815751   IPI00645074   IPI00816469   IPI00644480   IPI00646434   IPI00479140   IPI00641868   IPI00642406   IPI00642961   
Protein Interaction databases
Ontologies - Pathways
PubMed39 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Thu Mar 25 20:03:35 CET 2021

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us